Open main menu

Psychiatrienet β

Escitalopram-tranylcypromine

Revision as of 12:32, 21 October 2015 by Anoek (talk | contribs)
Escitalopram
Type Antidepressant
Group SSRI
links
Medscape Escitalopram
PubChem 10832572
PubMed Escitalopram
Kompas (Dutch) Escitalopram
Wikipedia Escitalopram
Tranylcypromine
Type Antidepressant
Group MAO-I
links
Medscape Tranylcypromine
PubChem 5530
PubMed Tranylcypromine
Kompas (Dutch) Tranylcypromine
Wikipedia Tranylcypromine

Switch medication from escitalopram to tranylcypromine.[1] [2]

Nietinrijdenbord.png Stop escitalopram
  • Before day 1: gradually reduce dosage of escitalopram to a maximum of 10 mg/day, when this dosage is >10 mg/day.
  • Day 1: reduce dosage of escitalopram to a maximum of 5 mg/day.
  • Day 8: stop administration of escitalopram.
Eenrichtingbord.png Start tranylcypromine
  • Day 9-23: a wash-out period of two weeks is necessary.
  • Day 24: Start administration of tranylcypromine in low dosage of 20 mg/day for one week.
  • Day 31: after this week the dosage of tranylcypromine can be increased if necessary.
Letopbord.png Cave
  • Occurrence of serotonin syndrome is reported when a wash-out period (of two weeks) is not considered.
  • The reduction of the SSRI doses in 7-14 days could cause emotional instability, headache and flu-like symptoms. One could extend this period.


  1. Switches are based on literature references on this page and expert opinions of the authors. The authors have used pharmacokinetic and receptor affinity properties to determine the switch schedules
  2. Stahl, S. M. (2013). Stahl's essential psychopharmacology: Neuroscientific basis and practical applications (4th ed.). Cambridge University Press.
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.